Online inquiry

IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5633MR)

This product GTTS-WQ5633MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5633MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11429MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ1448MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ4204MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ10841MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ5368MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ3064MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ12821MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ6760MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW